Document is current
Any future updates will be listed below
-
Authors
van Maldegem, Febe https://orcid.org/0000-0002-2544-544X
Valand, Karishma https://orcid.org/0000-0002-9158-5782
Cole, Megan https://orcid.org/0000-0002-6366-0642
Patel, Harshil https://orcid.org/0000-0003-2707-7940
Angelova, Mihaela https://orcid.org/0000-0002-0495-9695
Rana, Sareena
Colliver, Emma https://orcid.org/0000-0002-1497-0740
Enfield, Katey https://orcid.org/0000-0002-4551-6073
Bah, Nourdine
Kelly, Gavin https://orcid.org/0000-0001-7219-560X
Tsang, Victoria Siu Kwan https://orcid.org/0000-0002-0422-7371
Mugarza, Edurne
Moore, Christopher
Hobson, Philip
Levi, Dina
Molina-Arcas, Miriam
Swanton, Charles https://orcid.org/0000-0002-4299-3018
Downward, Julian https://orcid.org/0000-0002-2331-4729
- License Information
-
More Information
Article History
Received: 5 March 2021
Accepted: 20 September 2021
First Online: 8 October 2021
Competing interests
: J.D. has acted as a consultant for AstraZeneca, Bayer, Jubilant, Theras, Vividion and Novartis, and has funded research agreements with BMS, Revolution Medicines and Boehringer Ingelheim. C.S. receives grant support from Archer Dx, AstraZeneca, Boehringer Ingelheim and Ono Pharmaceutical; has consulted for AstraZeneca, Bicycle Therapeutics, Celgene, Genentech, GRAIL, GSK, Illumina, Medicxi, MSD, Novartis and the Sarah Cannon Research Institute; receives grant support and has consulted for Bristol Myers Squibb, Pfizer and Roche–Ventana; is an advisory board member and is involved in trials sponsored by AstraZeneca; has stock options in Apogen Biotechnologies, Epic Sciences, GRAIL; and has stock options and is a co-founder of Achilles Therapeutics. The remaining authors declare no competing interests.
